UCB Biopharma's Staccato Alprazolam Trial Targets Prolonged Seizures in Patients 12 and Older
A study is underway to evaluate the efficacy and safety of Staccato alprazolam in terminating seizure episodes in patients aged 12 and older.
Phase III
Neurology / Epilepsy
Status
Active
Sponsor
UCB Biopharma
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of Staccato alprazolam by UCB Biopharma is significant as it targets a critical need in the epilepsy treatment landscape for patients experiencing prolonged seizures. Positive outcomes could enhance UCB's competitive positioning and expand their neurology portfolio.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety outcomes, particularly the success rate in terminating seizures within the specified timeframe.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.